Journal of Cutaneous Immunology and Allergy最新文献

{"title":"Autosomal recessive hyper-IgE syndrome due to DOCK8 deficiency: An adjunctive role for omalizumab","authors":"Kim Han Nguyen MD,&nbsp;Quynh Anh Nguyen MD, MSc,&nbsp;Mai Hoang Tran MSc,&nbsp;Thu Thuy Can BS,&nbsp;Mai Thi Vu MD, MSc,&nbsp;Nam Sy Vo PhD,&nbsp;Hieu Chu Chi PhD,&nbsp;Sheryl van Nunen MBBS, MM(Sleep Medicine), FRACP,&nbsp;Dinh Van Nguyen MD, PhD","doi":"10.1002/cia2.12273","DOIUrl":"10.1002/cia2.12273","url":null,"abstract":"<p>Autosomal recessive hyper-IgE syndrome (AR-HIES) is a rare primary immunodeficiency disorder characterized by high serum IgE levels, recurrent viral skin infections, severe allergies, and early-onset malignancies, associated with mutations in the gene encoding the dedicator of cytokinesis 8 protein (DOCK8). We report a rare case of AR-HIES with DOCK8 deficiency in a young Japanese male with a past medical history of chronic atopic dermatitis, severe food allergies, and severe herpes simplex virus infection. Treatment was successfully based on infection management, skincare, and dietary elimination. In addition, anti-IgE therapy with omalizumab was the target treatment for this syndrome.</p>","PeriodicalId":15543,"journal":{"name":"Journal of Cutaneous Immunology and Allergy","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2022-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cia2.12273","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48479959","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Persistent varicella zoster virus infection following mRNA COVID-19 vaccination was associated with the presence of encoded spike protein in the lesion","authors":"Mayuko Yamamoto MD, PhD,&nbsp;Misaki Kase MD,&nbsp;Hozumi Sano MD,&nbsp;Reiko Kamijima,&nbsp;Shigetoshi Sano MD, PhD","doi":"10.1002/cia2.12278","DOIUrl":"10.1002/cia2.12278","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Since the campaign of vaccination against COVID-19 was started, a wide variety of cutaneous adverse effects after vaccination has been documented worldwide. Varicella zoster virus (VZV) reactivation was reportedly the most frequent cutaneous reaction in men after administration of mRNA COVID-19 vaccines, especially BNT162b2.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>A patient, who had persistent skin lesions after BNT162b2 vaccination for such a long duration over 3 months, was investigated for VZV virus and any involvement of vaccine-derived spike protein.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Materials &amp; Methods</h3>\u0000 \u0000 <p>Immunohistochemistry for detection of VZV virus and the spike protein encoded by mRNA COVID-19 vaccine. PCR analysis for VZV virus.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The diagnosis of VZV infection was made for these lesions using PCR analyses and immunohistochemistry. Strikingly, the vaccine-encoded spike protein of the COVID-19 virus was expressed in the vesicular keratinocytes and endothelial cells in the dermis.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Discussion</h3>\u0000 \u0000 <p>mRNA COVID-19 vaccination might induce persistent VZV reactivation through perturbing the immune system, although it remained elusive whether the expressed spike protein played a pathogenic role.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>We presented a case of persistent VZV infection following mRNA COVID-19 vaccination and the presence of spike protein in the affected skin. Further vigilance of the vaccine side effect and investigation for the role of SP is warranted.</p>\u0000 </section>\u0000 </div>","PeriodicalId":15543,"journal":{"name":"Journal of Cutaneous Immunology and Allergy","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2022-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cia2.12278","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41280893","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A case of COVID-19 with pernio-like skin lesions and increased red blood cell distribution width","authors":"Satoko Minakawa MD, PhD,&nbsp;Yasushi Matsuzaki MD, PhD,&nbsp;Akari Terada MD,&nbsp;Shu Ogasawara PhD,&nbsp;Yuki Nishiya MD, PhD,&nbsp;Jin Irie MD, PhD,&nbsp;Yoshiya Ishizawa MD, PhD,&nbsp;Hiroyuki Hanada MD, PhD,&nbsp;Daisuke Sawamura MD, PhD","doi":"10.1002/cia2.12272","DOIUrl":"10.1002/cia2.12272","url":null,"abstract":"<p>Coronavirus disease 2019 (COVID-19) is related to cutaneous manifestations.<span>¹</span> Previous reports indicate that pernio-like lesions are cutaneous manifestations of COVID-19.<span>^{1, 2}</span> We report a case of pernio-like lesions related to COVID-19.</p><p>A 74-year-old Japanese woman with diabetes and hypertension was diagnosed with COVID-19. She was living with her daughter's family, who had also been diagnosed with COVID-19. On illness day 6, she presented to our emergency department with malaise and worsening shortness of breath (saturation percentage of oxygen in the artery blood 74%). The chest radiograph detected her bilateral interstitial pneumonia, and the treatment of artificial respiration started. Favipiravir, dexamethasone, remdesivir, and empiric antibiotic therapy were administrated because of a positive blood culture (<i>Corynebacterium striatum</i>, <i>Klebsiella</i> species). She was given lactulose, subcutaneous low molecular heparin, and continuous intravenous heparin infusion for prevent COVID-19-related thrombosis. On illness day 13, her breathing became worse. Extracorporeal membrane oxygenation was started. On illness day 25, erythema was seen on her body. On illness day 27, erythema and maculopapular exanthema appeared on her trunk (Figure 1A), legs (Figure 1B), and hands (Figure 1C). A hemorrhagic rash appeared on her hands (Figure 1D). Pernio-like lesions were seen on her fingers (Figure 1E,F) and toes. Laboratory inspection clarified a normal white blood cell count (5860/mm), normal liver and kidney function, decreased hemoglobin (10.1 g/dl; normal range: 10.6–14.4 g/dl), hematocrit (31.5%; normal range: 32.1%–42.7%), platelet count (45,000/mm; normal range: 13,800–309,000/mm), increased C-reactive protein (CRP, 10.56 mg/dl; normal range &lt;0.3 mg/dl), lactate dehydrogenase (LD, 346 U/L; normal range: 119–229 U/L), fibrinogen-fibrin degradation product (FDP, 113.8 μg/ml; normal range &lt;5.0 μg/ml), dimerized plasmin fragment D (D-dimer, 55.5 μg/ml; normal range &lt;1.0 μg/ml), and red blood cell distribution width (RDW, 16.2%; normal range 11.5%–13.8%). Over the following days, gradual spontaneous improvement of skin lesions occurred. However, she became the cerebral infarction and died on illness day 44.</p><p>Previous studies found that 318 of 505 (63%) patients with dermatologic symptoms related to COVID-19 had pernio-like lesions.<span>³</span> Pernio-like lesions were sole symptoms in the 55% of patients.<span>³</span> Retiform purpura presented entirely in inpatients.<span>¹</span> Mechanisms of COVID-19 coagulopathy have been proposed. In a hypercoagulable situation, the crosstalk between the inflammatory and hemostatic systems may advance for thrombosis in COVID-19.<span>⁴</span> Heparin resistance was observed in patients with COVID-19 infectious disease of the serious case.<span>⁴</span></p><p>Elevated RDW is associate","PeriodicalId":15543,"journal":{"name":"Journal of Cutaneous Immunology and Allergy","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2022-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cia2.12272","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46142502","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A case of patch granuloma annulare with CD68-negative, CD163-positive M2 macrophages infiltration in an interstitial pattern","authors":"Kenta Ikeda MD,&nbsp;Kazuko Mizuno MD, PhD,&nbsp;Osamu Yamasaki MD, PhD,&nbsp;Shin Morizane MD, PhD","doi":"10.1002/cia2.12260","DOIUrl":"10.1002/cia2.12260","url":null,"abstract":"<p>Patch granuloma annulare is a rare type of granuloma annulare. Histopathologically, patch granuloma annulare shows interstitial infiltration of histiocytes. In our case, immunohistochemical analyses demonstrated CD68-negative, CD163-positive M2 macrophages infiltration in an interstitial pattern.\u0000 <figure>\u0000 <div><picture>\u0000 <source></source></picture><p></p>\u0000 </div>\u0000 </figure></p>","PeriodicalId":15543,"journal":{"name":"Journal of Cutaneous Immunology and Allergy","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2022-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cia2.12260","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44426435","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of sweating responses in patients with systemic connective tissue disorders using the quantitative sudomotor axon reflex test","authors":"Miwa Ashida MD,&nbsp;Shimpei Morimoto PhD,&nbsp;Mariko Yozaki MT,&nbsp;Daisuke Ehara MD,&nbsp;Yuta Koike MD, PhD,&nbsp;Hiroyuki Murota MD, PhD","doi":"10.1002/cia2.12269","DOIUrl":"10.1002/cia2.12269","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>In systemic connective tissue disorders, eccrine sweat glands are frequently attacked by immune cells, as evidenced by pathological observations.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>Sweating affects vascular activity through the autonomic nervous system, while few studies have reported sweating ability in systemic connective tissue disorders or the relationship between sweating ability and Raynaud's phenomenon caused by sympathetic hyperreactivity.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Materials &amp; methods</h3>\u0000 \u0000 <p>We performed the quantitative sudomotor axon reflex test on 85 patients diagnosed with systemic sclerosis, mixed connective tissue disease, systemic lupus erythematosus, Sjogren's syndrome, and dermatomyositis. Evaluations were performed once in summer and once in winter. We investigated the relationship between the axon reflex sweat volume or the reaction time and Raynaud's phenomenon assessed by a Raynaud's condition score, skin symptoms such as nailfold capillary changes, skin sclerosis severity, digital ulcers, chilblains, subcutaneous calcifications, and telangiectasia, and patient background.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Most patients did not show a decrease in sweating compared to healthy participants, but patients with systemic sclerosis who were positive for anti-RNA polymerase III antibodies showed little or no sweating. One in three patients showed less sweating in summer than in winter, which is the opposite of the normal seasonal variation. Although no relationship was observed between the sweat volume and the total Raynaud's condition scores, patients with pain had more sweating than those without pain.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>This is the first exploratory observational study of sweating ability in patients with systemic connective tissue disorders, revealing several clinical factors associated with acetylcholine-induced sweating.</p>\u0000 </section>\u0000 </div>","PeriodicalId":15543,"journal":{"name":"Journal of Cutaneous Immunology and Allergy","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2022-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cia2.12269","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47547572","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A case of psoriasiform drug eruption caused by temozolomide","authors":"Tokuko Oguro MD,&nbsp;Kimiko Nakajima MD, PhD,&nbsp;Natsuko Aoki MD,&nbsp;Mayuko Yamamoto MD, PhD,&nbsp;Shigetoshi Sano MD, PhD","doi":"10.1002/cia2.12263","DOIUrl":"10.1002/cia2.12263","url":null,"abstract":"<p>Psoriasiform drug eruption is defined as condition similar to psoriasis triggered by drug administration, including <i>de novo</i> development of psoriasis or exacerbation of pre-existing psoriasis. Herein, we describe a 52-year-old Japanese woman, who developed disseminated psoriasiform lesions following administration of temozolomide, a remedy for glioblastoma, although cutaneous adverse events by this drug was very rare. In addition, we assume that altered inflammatory signals associated with psoriasis, such as activation of signal transducer and activator of transcription 3 (STAT3), might be involved in the underlying pathomechanism of drug eruption caused by temozolomide.</p>","PeriodicalId":15543,"journal":{"name":"Journal of Cutaneous Immunology and Allergy","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2022-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cia2.12263","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41791066","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Malignant melanoma of inner canthus with long-term survival after resection of brain metastasis and treatment with ipilimumab","authors":"Masahito Yasuda MD, PhD,&nbsp;Akihito Uehara MD, PhD,&nbsp;Shintaro Saito MD,&nbsp;Yuko Kuriyama MD, PhD,&nbsp;Kazuya Yamada MD, PhD,&nbsp;Aina Oka MD,&nbsp;Marie Miyagawa MD,&nbsp;Osamu Ishikawa MD, PhD,&nbsp;Sei-Ichiro Motegi MD, PhD","doi":"10.1002/cia2.12268","DOIUrl":"10.1002/cia2.12268","url":null,"abstract":"<p>Cerebellar metastasis from malignant melanoma of the inner canthus was resected. The patient was subsequently treated with ipilimumab and has remained disease-free 6 years, however, developed sarcoidosis.\u0000 <figure>\u0000 <div><picture>\u0000 <source></source></picture><p></p>\u0000 </div>\u0000 </figure></p>","PeriodicalId":15543,"journal":{"name":"Journal of Cutaneous Immunology and Allergy","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2022-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cia2.12268","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45825816","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Successful management of hereditary angioedema with icatibant during the postpartum period","authors":"Yukari Kondo MD,&nbsp;Aki Yoshimura MD,&nbsp;Noriko Azuma MD","doi":"10.1002/cia2.12267","DOIUrl":"10.1002/cia2.12267","url":null,"abstract":"<p>A. Facial swelling during a hereditary angioedema (HAE) attack. B. Computed tomography image of the abdomen with intestinal edema during an HAE attack. C. Histogram of the frequency of monthly HAE attacks during self-administration of icatibant. The asterisk indicates when HAE attacks were treated by on-demand injection of plasma-derived C1 inhibitor at the emergency room.\u0000 <figure>\u0000 <div><picture>\u0000 <source></source></picture><p></p>\u0000 </div>\u0000 </figure></p>","PeriodicalId":15543,"journal":{"name":"Journal of Cutaneous Immunology and Allergy","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2022-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cia2.12267","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44258398","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recurrent pregnancy-associated erythema annulare centrifugum in a single gestation period","authors":"Kie Imura MD,&nbsp;Yurika Masuda MD,&nbsp;Yuko Sano MD,&nbsp;Hiroaki Yagi MD, PhD","doi":"10.1002/cia2.12266","DOIUrl":"10.1002/cia2.12266","url":null,"abstract":"<p>Erythema annulare centrifugum (EAC) is reportedly related to many factors such as immunological disorders, infections, malignancies, foods, and drugs. Pregnancy-associated EAC is extremely rare, with only six cases reported in the literature.<span>^1-6</span> To date, there have been no reports of EAC that disappeared and recurred during a single gestation period.</p><p>A 34-year-old woman visited our department in the 36th week of her first pregnancy with asymptomatic multiple annular erythematous lesions on the legs. On the examination, the erythematous areas were slightly raised and had slight scales (Figure 1A, B). She reported that the eruption had first appeared in week 10 and spontaneously disappeared within 2 months, then reappeared in week 28 and gradually enlarged centrifugally and increased in number. This was confirmed in serial photographs she had taken. Skin biopsy revealed hyperkeratosis, parakeratosis, mild spongiosis in the epidermis, and a superficial perivascular lymphohistiocytic infiltrate (Figure 1C). She was in good health and had not taken any medication or vaccination during the pregnancy. She had a good pregnancy course except that the fetus was in the breech position. The laboratory test results were normal, including complete blood count, renal and hepatic functions indices, immunoglobulins, antinuclear antibodies, anti-SS-A and anti-SS-B antibodies, and rheumatoid factors. She had no evidence of Sjögren syndrome. She delivered a healthy baby by elective cesarean section in week 38. Although all the erythematous lesions had been increasing in number and enlarging until the delivery, they started to disappear within 2 days after the delivery and wholly resolved within 1 month without any treatment. No recurrence was observed during 4 years of follow-up.</p><p>In all six reported cases of pregnancy-associated EAC, including ours, eruptions appeared during the first pregnancy. The onset of the lesions occurred in week 12 in two cases and weeks 26–33 in four.<span>^1-6</span> The lesions improved in weeks 33–36 in two cases, and at 3 days to 1 month postpartum in four. These findings suggest that the change in maternal hormone levels during pregnancy is a crucial etiological factor.<span>⁵</span> The major possible causative candidates include estrogen, progesterone, and human chorionic gonadotropin (hCG).<span>⁶</span> The secretion of hCG differs from that of the other hormones and many other placental proteins. hCG is first detected in maternal serum within 9 days after conception. The hCG levels then rise in a logarithmic fashion, peaking at 8–10 weeks after the last menstrual period, followed by a decline to a nadir at 18 weeks, with subsequent levels remaining constant or slightly increasing in some individuals until delivery.<span>^{7, 8}</span> The concentrations of estrogen and progesterone gradually increase and are maintained at high concentrations until deliv","PeriodicalId":15543,"journal":{"name":"Journal of Cutaneous Immunology and Allergy","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2022-07-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cia2.12266","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45861035","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prior antihistamine agent successfully impaired cutaneous adverse reactions to COVID-19 vaccine","authors":"Hikaru Nanamori MD,&nbsp;Yu Sawada MD, PhD,&nbsp;Sayaka Sato MD,&nbsp;Reiko Hara MD,&nbsp;Yoko Minokawa MD,&nbsp;Hitomi Sugino MD,&nbsp;Natsuko Saito-Sasaki MD, PhD,&nbsp;Kayo Yamamoto MD,&nbsp;Etsuko Okada MD, PhD,&nbsp;Motonobu Nakamura MD, PhD","doi":"10.1002/cia2.12248","DOIUrl":"10.1002/cia2.12248","url":null,"abstract":"<p>The coronavirus disease 2019 (COVID-19) vaccine is positively changing the health crises of this pandemic and is currently essential to overcome the COVID-19 pandemic. The vaccine shows high efficacy against the infection and impairs the severity of symptoms. However, this vaccination is associated with concerns, such as vaccine-associated adverse reactions, which are currently highlighted issues for clinicians. We experienced two cases of mild cutaneous adverse reaction following COVID-19 vaccine administration, which was successfully controlled by prior administration of the antihistamine agent fexofenadine 3 days before COVID-19 vaccination for 7 days.</p>","PeriodicalId":15543,"journal":{"name":"Journal of Cutaneous Immunology and Allergy","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2022-07-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cia2.12248","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47096943","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}